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Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by fibrillar
cytoplasmic aggregates of α-synuclein (i.e., Lewy bodies) and the associated loss of dopaminergic
cells in the substantia nigra. Mutations in genes such as α-synuclein (SNCA) account for only 10% of
PD occurrences. Exposure to environmental toxicants including pesticides and metals (e.g., paraquat
(PQ) and manganese (Mn)) is also recognized as an important PD risk factor. Thus, aging, genetic
alterations, and environmental factors all contribute to the etiology of PD. In fact, both genetic and
environmental factors are thought to interact in the promotion of idiopathic PD, but the mechanisms
involved are still unclear. In this study, we summarize our findings to date regarding the toxic
synergistic effect between α-synuclein and paraquat treatment. We identified an essential role for
central carbon (glucose) metabolism in dopaminergic cell death induced by paraquat treatment that is
enhanced by the overexpression of α-synuclein. PQ “hijacks” the pentose phosphate pathway (PPP)
to increase NADPH reducing equivalents and stimulate paraquat redox cycling, oxidative stress, and
cell death. PQ also stimulated an increase in glucose uptake, the translocation of glucose transporters
to the plasma membrane, and AMP-activated protein kinase (AMPK) activation. The overexpression
of α-synuclein further stimulated an increase in glucose uptake and AMPK activity, but impaired
glucose metabolism, likely directing additional carbon to the PPP to supply paraquat redox cycling.
Keywords: Parkinson’s Disease; genetics; toxin synergy; molecular mechanisms; NMR; mass spectrometry
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Figure 1. Parkinson’s disease results from dopaminergic neuron cell death in the substantia nigra:
Figure 1. Parkinson’s disease results from dopaminergic neuron cell death in the substantia nigra: (a)
(a) In vivo imaging of dopaminergic activity in the Parkinsonian basal ganglia shown by [18 F]
In vivo imaging of dopaminergic activity in the Parkinsonian basal ganglia shown by [18F]
fluorodopa PET. The signal from striatum in a healthy control subject, a patient with symptomatic
fluorodopa PET. The signal from striatum in a healthy control subject, a patient with symptomatic
Parkinson’s disease and a twin who was asymptomatic at the time of scan but who subsequently
Parkinson’s disease and a twin who was asymptomatic at the time of scan but who subsequently
developed the disease. Reproduced with permission from [3]. (b) Schematic of the multiple factors that
developed the disease. Reproduced with permission from [3]. (b) Schematic of the multiple factors
contribute to the development of Parkinson’s disease. Both aging and environmental factors modify
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to thewhich
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1.2. PD and Environmental Risk Factors
1.2. PD and Environmental Risk Factors
The largest epidemiology study of PD in the USA identified a number of environmental factors
The largest epidemiology study of PD in the USA identified a number of environmental factors
correlated with an increased incidence of PD [22]. Specifically, PD was found to be more common
correlated with an increased incidence of PD [22]. Specifically, PD was found to be more common in
in the Midwest and the Northeast. In fact, the state of Nebraska was observed to have the highest
the Midwest and the Northeast. In fact, the state of Nebraska was observed to have the highest
prevalence of PD in the world (Table 1). Again, this is consistent with areas associated with agriculture
prevalence of PD in the world (Table 1). Again, this is consistent with areas associated with
agriculture and metal processing having high rates of PD. Thus, prolonged exposure to herbicides or

Metabolites 2017, 7, 22

3 of 26

and metal processing having high rates of PD. Thus, prolonged exposure to herbicides or insecticides
from farming or metals from industry likely contributes to PD. Consequently, paraquat (herbicide),
rotenone (insecticide), 6-hydroxydopamine (6-OHDA, neurotoxin), 1-methyl-4-phenylpyridinium
(MPP+ , herbicide), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, prodrug), and manganese
have all been shown to induce PD-like symptoms. These compounds are routinely and interchangeably
used to induce dopaminergic neuron cell death and as chemical mimics of PD in animal models.
MPTP was discovered as a contaminant in illicit opioid synthesis, and acts as a prodrug that is
converted to MPP+ in the brain and is selectively taken up by dopaminergic cells [23,24]. MPP+ inhibits
mitochondrial respiratory complex I of the electron transport chain and interferes with oxidative
phosphorylation in the mitochondria [25,26]. Paraquat has a structure similar to MPTP, but is a poor
inhibitor of complex I. Instead, paraquat toxicity has been primarily attributed to its redox cycling that
generates reactive oxygen species (ROS). Paraquat is reported to induce dopaminergic degeneration
in vivo, which is one of the pathological hallmarks of PD, but contradictory results exist as well. While
some environmental toxicants linked to PD such as PQ have been demonstrated to have a limited
capacity to diffuse across the blood–brain barrier (BBB) [27,28], a significant increase in the permeability
of the BBB in the postcommissural putamen of PD patients has been reported [29] and breakdown of
the BBB has been shown to occur during aging [30]. Interestingly, α-synuclein impairs tight junction
protein expression [30]. These findings again suggest the likelihood that neurodegeneration linked to
environmental exposure is a consequence of genetics and or aging converging to promote dopaminergic
cell loss.
The chemical similarity between paraquat and MPTP initiated an investigation into an agricultural
link with PD. Consequently, a correlation between paraquat agricultural usage and PD rates has been
observed. The naturally occurring insecticide rotenone also inhibits complex I, which leads to energy
failure and cell death [31,32]. Similarly, 6-OHDA has been proposed to induce dopaminergic neuron
cell death by producing pro-oxidant capacity and selective uptake via dopamine transporters [23,33,34].
Table 1. Prevalence of PD in Nebraska [35].
Age (Years)
Nebraska PD Prevalence
(Rates per 100,000)
Men
Women

60–70

70–80

80+

406
298

1794
991

4248
2069

Regardless of the environmental toxin, there appears to be a common mechanism that leads
to dopaminergic neuron cell death. Neurons have a very high energy demand and high glucose
usage. Consequently, alterations in energy metabolism have been reported in early PD. Specifically,
environmental toxins alter redox homeostasis, energy metabolism, and central carbon metabolism.
Environmental toxins appear to increase ROS either through a direct redox cycling or indirectly by
inhibiting the electron transport chain. Consequently, this leads to dysfunctional mitochondria and cell
death. Thus, toxin-induced alterations in metabolic pathways important to central carbon metabolism,
energy metabolism and redox homeostasis present a clear role for metabolomics in investigating PD.
1.3. Lewy Bodies and α-Synuclein
A hallmark of PD is the formation of intracellular protein aggregates or Lewy bodies in the
dopaminergic neurons within the substantia nigra (Figure 2a) [36]. Lewy bodies are found in the
cytoplasm as single or multiple spherical masses consisting of a dense protein core surrounded by a
pale halo. Lewy bodies have a filamentous structure and contain over 70 different biological molecules
falling within 10 distinct classes. α-Synuclein is a major component of Lewy bodies and forms the fibrils
(Figure 2b) [37,38]. In addition to α-synuclein fibrils, other components of Lewy bodies correspond to
proteins involved in: (i) α-synuclein binding; (ii) synphilin-1-binding; (iii) ubiquitin-proteasome system;
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(iv) cellular responses; (v) phosphorylation and signal transduction; (vi) cytoskeleton; and (vii) the cell
Metabolites 2017, 7, 22
4 of 26
cycle. Importantly, Lewy bodies are correlated with neuronal loss and cognitive impairment, which
suggests
neurons that
contain
Lewy
bodies
are dying.
However,
there
is noare
evidence
Lewy
cognitivethat
impairment,
which
suggests
that
neurons
that contain
Lewy
bodies
dying. that
However,
bodies
are
the
actual
cause
of
cell
death.
In
fact,
Lewy
bodies
may
be
a
cytoprotective
mechanism
there is no evidence that Lewy bodies are the actual cause of cell death. In fact, Lewy bodies may beina
PD,
while α-synuclein
protofibrils
cytotoxic agents.
Lewymight
bodiesbe
may
functionagents.
to sequester
cytoprotective
mechanism
in PD, might
while be
α-synuclein
protofibrils
cytotoxic
Lewy
and
degrade
the
α-synuclein
fibrils.
bodies may function to sequester and degrade the α-synuclein fibrils.

(a)

(b)

Figure 2. (a) Substantia nigra from patients with Parkinson’s disease (from the MRC Cambridge
Figure 2. (a) Substantia nigra from patients with Parkinson’s disease (from the MRC Cambridge Brain
Brain Bank) immunostained for α-synuclein. (Top) Two pigmented nerve cells, each containing an
Bank) immunostained for α-synuclein. (top) Two pigmented nerve cells, each containing an
α-synuclein-positive Lewy body (long arrows). Lewy neurites (short arrows) are also immunopositive.
α-synuclein-positive Lewy body (long arrows). Lewy neurites (short arrows) are also immunopositive.
Scale bar, 20 µm. (Bottom Left) A pigmented nerve cell with two α-synuclein-positive Lewy bodies.
Scale bar, 20 μm. (bottom left) A pigmented nerve cell with two α-synuclein-positive Lewy bodies.
Scale bar, 8 µm. (Bottom Right) α-Synuclein-positive, extracellular Lewy body. Scale bar, 4 µm.
Scale bar, 8 μm.
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Figure 3. Structure of α-synuclein: (a) Schematic representation of micelle-bound α-synuclein (α-syn;
Figure 3. Structure of α-synuclein: (a) Schematic representation of micelle-bound α-synuclein (α-syn;
Protein Data Bank ID: 1XQ8) [40]. The N-terminal region, the non-amyloid-β component of Alzheimer’s
Protein Data Bank ID: 1XQ8) [40]. The N-terminal region, the non-amyloid-β component of
disease amyloid plaques (NAC) region and the C-terminal part are colored blue, orange and red,
Alzheimer’s disease amyloid plaques (NAC) region and the C-terminal part are colored blue, orange
respectively. Numbers refer to amino acid residues flanking the different regions. Reproduced with
and red, respectively. Numbers refer to amino acid residues flanking the different regions.
permission from [39]. (b) α-Synuclein protein domain structure. α-Syn is a 140-amino-acid protein
Reproduced with permission from [39]. (b) α-Synuclein protein domain structure. α-Syn is a
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2. NMR and MS Metabolomics Protocol to Investigate PD
2.1. Combining NMR and MS Improves Coverage of the Metabolome
2.1. Combining NMR and MS Improves Coverage of the Metabolome
Nuclear magnetic resonance (NMR) [64] and mass spectrometry (MS) [65] have been the primary
Nuclear
magnetic
resonance
(NMR) [64]
and mass
spectrometry
(MS)
have
been
analytical tools
used to obtain
metabolomics
datasets.
Historically,
only NMR
or [65]
MS has
been
usedthe
for
primary analytical tools used to obtain metabolomics datasets. Historically, only NMR or MS has
been used for a given metabolomics study, in which the choice of instrumentation has been
primarily decided upon based on an investigator’s experience and expertise, instead of the needs of
the study. Consequently, a suboptimal analysis of the metabolome is likely to occur. In fact, NMR
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a given metabolomics study, in which the choice of instrumentation has been primarily decided upon
based on an investigator’s experience and expertise, instead of the needs of the study. Consequently,
a suboptimal analysis of the metabolome is likely to occur. In fact, NMR and MS are inherently
complementary and when employed together provide a broader and more accurate coverage of the
metabolome [66,67]. While the number of studies is still limited, a few projects that have used both
NMR and MS have observed a common trend [68–70]. A set of metabolites was only observable by
NMR, while a second set of metabolites was only detected by MS. A smaller subset of metabolites was
observed by both NMR and MS. Simply, NMR only observes the most abundant metabolites (≥1 µM)
and MS only observes the metabolites that readily ionize. There are other important differences
between NMR and MS. NMR requires minimal sample handling before data collection, is easily
quantifiable, and provides multiple means of metabolite identification. In addition to the higher
sensitivity, (femtomolar to attomolar), MS also has a higher resolution (~103 –104 ) and dynamic range
(~103 –104 ). However, chromatography is commonly required for MS because of the relatively narrow
nominal mass and mass defect distribution of the metabolome [71]. The use of chromatography has its
own limitations and may also lead to a loss of observable metabolites for a variety of reasons [72–76].
Simply, NMR and MS have unique sets of strengths and limitations and both analytical methods
beneficially contribute to a metabolomics study. In fact, a number of recent methods highlight the
benefits of combining NMR and MS to improve the accuracy of metabolite identification or for
identifying unknown metabolites [77–81].
2.2. Combined NMR and MS Metabolomics Methodology
Towards this end, we recently optimized sample preparation, data collection, and data handling
protocols to effectively integrate direct-infusion electrospray ionization mass spectrometry (DI-ESI-MS)
data with 1D 1 H NMR spectra (Figure 4) [82,83]. By splitting metabolite extracts optimized for NMR
acquisition and by diluting the MS-bound aliquots tenfold in H2 O/methanol/formic acid (49.57 :
49.75 : 0.5), we obtained samples suitable for NMR and DI-ESI-MS while avoiding chromatographic
separations. We also optimized several DI-ESI-MS ion source conditions to maximize the quality of
the MS metabolomics data: sampling cone voltage (SCV) of 40 V, extraction voltage (ECV) of 4.0 V,
desolvation temperature of 150 ◦ C, desolvation gas flow of 500 L/h, and a cone gas flow of 0 L/h.
We preprocessed the acquired mass spectra with background subtraction, followed by uniform binning
with a 0.5 m/z bin size and spectral noise region removal. NMR spectra were processed with our
MVAPACK [84] software and automatically phased and normalized using our phase-scatter correction
(PSC) algorithm [85]. Chemical shift regions containing spectral baseline noise or solvent signals
were removed based on our previously developed protocols [86,87]. Binning was performed using
an adaptive intelligent binning algorithm [88] implemented in MVAPACK [84] that minimizes the
splitting of signals between multiple bins.
Integrating MS and NMR data clearly resulted in better class separation and tighter within-class
variation than using only NMR or MS datasets (Figure 5). This was accomplished by incorporating
multivariate statistical techniques to properly handle multiple analytical datasets [89–91]—multiblock
principal component analysis (MB-PCA) and multiblock partial least squares (MB-PLS)—into
MVAPACK [84]. Multiblock methods are similar to traditional PLS and PCA, but provide a means
for analyzing data from multiple analytical sources [89–91]. Simply put, the NMR and MS spectral
data are placed into separate “blocks,” which allows for the generation and simultaneous usage of
within-block and between-block data correlations. The inclusion of MB-PLS also led to the use of
backscaled loadings to identify biologically important metabolites that contributed significantly to
group separation. Importantly, these NMR and MS spectral changes are now identified as being
statistically correlated. In addition to MB-PCA and MB-PLS, the data were jointly modeled using
multiblock orthogonal projections to latent structures (MB-OPLS), which corroborated the MB-PLS
analysis while better differentiating group separations [92]. By effectively integrating NMR and MS
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Figure 5. Scores generated from (a) PCA of 1D1 1 H NMR spectra; (b) PCA of DI-ESI-MS spectra;
Figure 5. Scores generated from (a) PCA of 1D H NMR spectra; (b) PCA of DI-ESI-MS spectra; and
and (c) MB-PCA of 1D1 1 H NMR and DI-ESI-MS spectra of metabolomes extracted from human
(c) MB-PCA of 1D H NMR and DI-ESI-MS spectra of metabolomes extracted from human
dopaminergic neuroblastoma cells treated with environmental/mitochondrial toxins. The ellipses
dopaminergic neuroblastoma cells treated with environmental/mitochondrial toxins. The ellipses in
in the PCA score plots correspond to the 95% confidence limits from a normal distribution for each
the PCA score plots correspond to the 95% confidence limits from a normal distribution for each
cluster. Symbols designate the following classes: Control (•); Rotenone (•); 6-OHDA (•); MPP+ (•);
cluster. Symbols designate the following classes: Control (●); Rotenone (●); 6-OHDA (●); MPP+ (●);
and Paraquat (•). Reproduced with permission from [82].
and Paraquat (●). Reproduced with permission from [82].
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3. PD and Mitochondrial/Environmental Toxins
3.1. Paraquat Induces Unique Metabolic Changes
3.1. Paraquat Induces Unique Metabolic Changes
In a previous study, human dopaminergic neuroblastoma cells (SK-N-SH) were treated with sublethal
In a previous study, human dopaminergic neuroblastoma cells (SK-N-SH) were treated with
doses of environmental toxins known to induce dopaminergic cell death. Specifically, cells were treated
sublethal doses of environmental toxins known to induce dopaminergic cell death. Specifically, cells
with MPP+ , 50 µM 6-OHDA, 0.5 mM paraquat, or 4.0 µM rotenone for 24 h [82,83]. The metabolome
were treated with MPP+, 50 μM 6-OHDA, 0.5 mM paraquat, or 4.0 μM rotenone for 24 h [82,83]. The
was extracted as described above (Figure 4) and analyzed with both 1D 1 H NMR and DI-ESI-MS.
metabolome was extracted as described above (Figure 4) and analyzed with both 1D 1H NMR and
The resulting MB-PCA model (Figure 5c) was valid based on both a CV-ANOVA p value of 1.7 × 10−12
DI-ESI-MS. The resulting MB-PCA model (Figure 5c) was valid based on both a CV-ANOVA p value of
and response permutation testing that yielded a p value equal to zero. The MB-PCA model yielded a
1.7 × 10−12 and response permutation testing that yielded a p value equal to zero. The MB-PCA model
clear separation between the control group and the four toxin treatments. Furthermore, the control and
yielded a clear separation between the control group and the four toxin treatments. Furthermore, the
paraquat groups were separated from the other toxin treatments. Also, the MPP+ treatment group was
control and paraquat groups were separated from the other toxin treatments. Also, the MPP+ treatment
significantly separated from 6-OHDA and rotenone treatments. Again, these group separations were
group was significantly separated from 6-OHDA and rotenone treatments. Again, these group
not apparent if only the NMR or MS dataset was used (Figure 5). More importantly, 6-OHDA, MPP+ ,
separations were not apparent if only the NMR or MS dataset was used (Figure 5). More importantly,
paraquat, and rotenone have been routinely used as experimental models of PD since they all result
6-OHDA, MPP+, paraquat, and rotenone have been routinely used as experimental models of PD since
to a certain and variable extent in dopaminergic neuron cell death and PD-like symptoms in animal
they all result to a certain and variable extent in dopaminergic neuron cell death and PD-like symptoms
models [93]. Nevertheless, our analysis clearly indicates that the metabolic impact of these four toxins
in animal models [93]. Nevertheless, our analysis clearly indicates that the metabolic impact of these four
is unique and, consequently, the molecular mechanism that results in neuronal cell death must be
toxins is unique and, consequently, the molecular mechanism that results in neuronal cell death must be
different. Since paraquat treatment resulted in the largest metabolome changes relative to untreated
different. Since paraquat treatment resulted in the largest metabolome changes relative to untreated
controls, we focused our further investigation on the molecular mechanism of PD on paraquat.
controls, we focused our further investigation on the molecular mechanism of PD on paraquat.
A detailed analysis of the metabolic changes by NMR and MS verified that paraquat uniquely
A detailed analysis of the metabolic changes by NMR and MS verified that paraquat uniquely
perturbed the metabolome of dopaminergic neurons. For example, the S-plot (Figure 6a) generated
perturbed the metabolome of dopaminergic neurons. For example, the S-plot (Figure 6a) generated
from the MB-PLS-DA model identified metabolites significantly perturbed in dopaminergic neurons
from the MB-PLS-DA model identified metabolites significantly perturbed in dopaminergic neurons
following paraquat treatment. Specifically, an increase in citrate, glucose 6-phosphate/fructose
following paraquat treatment. Specifically, an increase in citrate, glucose 6-phosphate/fructose
6-phoshate, heptose (sedoheptulose), and hexose (glucose or myoinositol), and a decrease in lactate,
glutamate, dopamine, and phospho-aspartate were clearly observed. A similar comparison was made
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Figure 6. (a) Alterations in citrate, glucose 6-phosphate/fructose 6-phosphate, lactate, and glucose
Figure 6. (a) Alterations in citrate, glucose 6-phosphate/fructose 6-phosphate, lactate, and glucose
content are specific for paraquat treatment. S-plot was generated from the combined MB-PLS-DA of 1D
are specific for paraquat treatment. S-plot was generated from the combined MB-PLS-DA of 1D
1content
H NMR spectra and DI-ESI-MS spectra. The S-plot was used to identify metabolites that significantly
1H NMR spectra and DI-ESI-MS spectra. The S-plot was used to identify metabolites that significantly
contribute to the class separation between untreated controls and paraquat treatment. The metabolites
contribute to the class separation between untreated controls and paraquat treatment. The metabolites
located in the upper right quadrant increased significantly while those located in the lower left quadrant
located in the upper right quadrant increased significantly while those located in the lower left
significantly decreased after paraquat exposure. Reproduced with permission from [83]. (b) Western
quadrant significantly decreased after paraquat exposure. Reproduced with permission from [83]. (b)
blot analysis of changes in glucose-6-phosphate dehydrogenase (G6PD) expression induced by
Western blot analysis of changes in glucose-6-phosphate dehydrogenase (G6PD) expression induced
paraquat. Paraquat induces an increase in the expression levels of G6PD. Glyceraldehyde 3-phosphate
by paraquat. Paraquat induces an increase in the expression levels of G6PD. Glyceraldehyde
dehydrogenase (GAPDH) levels are used as loading controls for WBs. The changes observed in
3-phosphate dehydrogenase (GAPDH) levels are used as loading controls for WBs. The changes
GAPDH levels might reflect of overall cell death (overall decrease in protein content) induced by PQ.
observed in with
GAPDH
levels might
reflect of overall cell death (overall decrease in protein content)
Reproduced
permission
from [83].
induced by PQ. Reproduced with permission from [83].
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Figure 7. Paraquat induces selective changes in glucose metabolism, TCA cycle, and the PPP pathway.
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particular interest since it is a rate-limiting enzyme of the PPP and a major source of NADPH [97].
The proteomics data were confirmed by Western blot (Figure 6b) and indicate that G6PD expression
increased proportional to an increase in paraquat dosage. Thus, the metabolomics and proteomics
data indicated that alterations in PPP and G6PD activity may be a result of paraquat toxicity.

Metabolites 2017, 7, 22

11 of 26

3.3. Paraquat Hijacks the Pentose Phosphate Pathway
Metabolites 2017, 7, 22

11 of 26
Human dopaminergic neuroblastoma cells were transduced with adenovirus
encoding for
human G6PD (AdG6PD) or empty adenovirus (AdEmpty) to further investigate the role of G6PD in
3.3. Paraquat
HijacksG6PD
the Pentose
Phosphate Pathway
paraquat
toxicity.
overexpression
increased cell death and oxidative death as a result of
paraquat
treatment,
but, importantly,
no change
was observed
when cells
were
Human
dopaminergic
neuroblastoma cells
were transduced
with adenovirus
encoding
forexposed
human to other
toxins
8a).orConversely,
paraquat-induced
toxicity,
mitochondrial
ROS formation,
G6PD(Figure
(AdG6PD)
empty adenovirus
(AdEmpty) to further
investigate
the role of G6PD
in paraquat and GSH
toxicity. G6PD
increased
cellwas
death
and oxidative
as a result of paraquat(6-AN)
treatment,
depletion
wereoverexpression
reversed when
G6PD
inhibited
withdeath
6-aminonicotinamide
(Figure 8b).
but,
importantly,
no
change
was
observed
when
cells
were
exposed
to
other
toxins
(Figure
8a).
Again, 6-AN had no effect on cell death or GSH depletion when neuronal cells were treated with
Conversely, paraquat-induced
toxicity, mitochondrial ROS formation, and GSH depletion were reversed
rotenone,
MPP+, or 6-OHDA
instead of paraquat. These observations are consistent with the
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Data
is
represented
cytometry using PI and mBCl. Cell death is observed as an increase in PI uptake. Data is represented
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as fold increase in the mean PI fluorescence and are means ± SE of three independent experiments. * p
* p < 0.05, Empty vs. G6PD values. Reproduced with permission from [83]. (b) Cell death induced by
< 0.05,
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succinate dehydrogenase (EC:1.3.5.1); TPI, triosephosphate isomerase (EC:5.3.1.1); TAL,
Reproduced with permission from [83].
transaldolase (EC:2.2.1.2); TKT, transketolase (EC:2.2.1.1). Reproduced with permission from [83].

cells grown in glucose-free or galactose-supplemented media was verified by changes in the
extracellular medium acidification (ECAR) (Figure 10b). Furthermore, treatment of cells with
2-deoxy-D-glucose (2-DG), which is a hexokinase inhibitor that prevents the production of
glucose-6-phosphate, also provided protection from paraquat toxicity (Figure 10c). These results, in
Metabolites
2017, 7, 22 that glucose metabolism contributes to the death of cells following treatment
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Two-way ANOVA Holm–Sidak post hoc test: a, p < 0.05 vs. no PQ or MPP within the
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+glucose. Reproduced with permission from [98].
corresponding toxicant treatment. t-test: * p 0.05, vs. + glucose. Reproduced with permission from
[98].
The metabolomics analysis indicated both an increase in intracellular glucose and a corresponding
decrease in extracellular glucose after exposure to paraquat. These observations suggested that
paraquat treatment increases glucose uptake. A fluorescently labeled analog of glucose (2-[N-(7nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose, 2-NBDG) was used to monitor changes
in glucose uptake due to paraquat exposure. Correspondingly, neuronal cells treated with paraquat
exhibited a >60% increase in glucose uptake in response to paraquat treatment (Figure 11a), which
is consistent with the metabolomics data. Glucose uptake is regulated by a saturable transport
system involving the Na+-independent glucose transporters (GLUT), and the Na+-dependent glucose
transporters (SGLT). Exposure to paraquat resulted in a significant increase in the translocation of
SGLT1 and GLUT4 transporters to the plasma membrane. Consequently, inhibiting glucose uptake
with STF-31, a GLUT inhibitor, (Figure 11b) or ascorbic acid, a competitive inhibitor of glucose,
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decreased paraquat toxicity. Again, these results clearly demonstrate that glucose metabolism is an
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to paraquat-induced cell death.
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from [98].transport inhibitor) within the corresponding PQ concentration. Reproduced with
permission from [98].
3.5. Paraquat Induced Metabolic Dysfunction in the Mice Midbrain and Striatum

3.5. Paraquat
Induced Metabolic Dysfunction in the Mice Midbrain and Striatum
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uptake and, like other kinases, is regulated by phosphorylation (pAMPK) [99]. Consequently, chronic
Paraquat was again observed to induce a large accumulation of citrate consistent with the proposed
paraquat treatment also resulted in a significant increase in pAMPK and its substrate acetyl-CoA
inactivation
of aconitase. AMP-activated protein kinase (AMPK) is a metabolic master regulator that
carboxylase (pACC) only in the midbrain and striatum of C57BI/6 mice (Figure 12b). These results
includes
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glucose
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pAMPK and its substrate acetyl-CoA carboxylase (pACC) only in the midbrain and striatum of
C57BI/6 mice (Figure 12b). These results further corroborate the observation that paraquat
modulates glucose metabolism and that the midbrain and striatum are selectively sensitive to
paraquat toxicity.
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Figure 12. C57Bl/6J mice were exposed chronically to paraquat (PQ). One week after the final
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is likely
any significant change in viability (Figure 13a). Conversely, treatment with paraquat resulted in a
one component
in the development and progression of the disease. Overexpression and aggregation
significant increase in cell death and a major perturbation in the metabolome (Figure 13). Specifically,
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formationoverexpression
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there the
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The overexpression
metabolomerelationship
than either paraquat
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or α-synuclein
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the
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if
either
WT
or
A53T
α-synuclein
was
overexpressed.
A
detailed
analysis
of wild-type (WT) α-synuclein or an A53T mutant (familial PD mutant [9,10]) did not result in any
of the metabolic
changes
was then
made13a).
using Conversely,
2D 1 H-13 C HSQC
experiments
andparaquat
following the
significant
change in
viability
(Figure
treatment
with
resulted in a
13 C-carbon distribution resulting from 13 C-glucose supplemented media (Figure 14a). Overexpression
significant increase in cell death and a major perturbation in the metabolome (Figure 13).
of α-synuclein and paraquat exposure resulted in an enhanced glucose accumulation, an impairment
Specifically,
the and
combination
paraquat
and
overexpression
produced
a more
in glycolysis,
a reduction in of
glycolytic
capacity
andα-synuclein
mitochondrial respiration
(OCR/ECAR
ratio)
dramatic
change
(Figure
14b). in the metabolome than either paraquat treatment or α-synuclein overexpression

alone. Importantly, the same results were obtained if either WT or A53T α-synuclein was
overexpressed. A detailed analysis of the metabolic changes was then made using 2D 1H-13C HSQC
experiments and following the 13C-carbon distribution resulting from 13C-glucose supplemented
media (Figure 14a). Overexpression of α-synuclein and paraquat exposure resulted in an enhanced
glucose accumulation, an impairment in glycolysis, and a reduction in glycolytic capacity and
mitochondrial respiration (OCR/ECAR ratio) (Figure 14b).
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observed to prevent cell death from paraquat exposure (Figure 10). Furthermore, paraquat treatment
observed to prevent cell death from paraquat exposure (Figure 10). Furthermore, paraquat treatment
was shown to cause an increase in glucose uptake, and inhibiting glucose uptake was also shown
was shown
to cause Contributes
an increase in
uptake,
and inhibiting
glucose uptake
was also shown to
4.2. Glucose
Metabolism
to glucose
Synergistic
Toxicity
between Paraquat
and α-Synuclein

As described in Section 3.4, glucose metabolism was shown to regulate paraquat toxicity.
Specifically, glucose deprivation protected dopaminergic cells from paraquat-induced cell death.
Additionally, replacing glucose with galactose or the inhibition of glycolysis with 2-DG were also
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Conclusions
5.5.Conclusions
PD is
believed
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disease, in disease,
which age,ingenetics,
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risk
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The
overexpression
or
mutation
of
α-synuclein
[9,10] of
environmental toxins are all considered significant risk factors. The overexpression or mutation
has been identified as a major genetic factor associated with PD. In fact, the formation of α-synuclein
α-synuclein [9,10] has been identified as a major genetic factor associated with PD. In fact, the
aggregates or Lewy bodies in dopaminergic neurons are the primary clinical sign of the disease.
formation of α-synuclein aggregates or Lewy bodies in dopaminergic neurons are the primary
Lewy bodies are correlated with neuronal loss and cognitive impairment, which are key symptoms of
clinical sign of the disease. Lewy bodies are correlated with neuronal loss and cognitive impairment,
PD. The biological function of α-synuclein is currently unknown, and while a variety of factors
which are key symptoms of PD. The biological function of α-synuclein is currently unknown, and
have been shown to induce fibril formation, oxidative stress [49] is an important contributor.
while a variety of factors have been shown to induce fibril formation, oxidative stress [49] is an
Thus, mitochondrial dysfunction, energy failure, and redox imbalance induced by environmental
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16).
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leading
to dopaminergic
cell to
death.
We(Figure
have shown
that paraquat hijacks the NADPH from the PPP to redox cycle, induces oxidative damage, and
impairs antioxidant defenses. Furthermore, paraquat increases glucose transport and carbon flux to
the PPP (Figure 16). Finally, paraquat impairs the TCA cycle, which leads to the accumulation of
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Figure 16. Glucose metabolism and AMPK signaling regulate the toxicity of paraquat + α-synuclein.
Figure 16. Glucose metabolism and AMPK signaling regulate the toxicity of paraquat + α-synuclein.
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6. Future Perspectives
The work presented herein provides some insights into potential underlying molecular
mechanisms that lead to PD, specifically with regards to the herbicide paraquat. It also provides
valuable evidence in support of a gene–environment interaction that may increase the likelihood of
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6. Future Perspectives
The work presented herein provides some insights into potential underlying molecular
mechanisms that lead to PD, specifically with regards to the herbicide paraquat. It also provides
valuable evidence in support of a gene–environment interaction that may increase the likelihood of
developing PD. Nevertheless, the molecular mechanism attributed to other environmental toxins is still
currently unknown. Additionally, the biological role in PD for other genetic alterations (i.e., Parkin, DJ-1,
PINK1, and LRRK2) requires further investigation. Even in the case of α-synuclein, the mechanism
by which α-synuclein interacts with paraquat to induce cell death is still unclear. For example, it is
still uncertain if α-synuclein aggregates are a direct cause of neuronal cell death or if the formation of
Lewy bodies is a protective mechanism. Similarly, while some evidence was provided that cell-based
results are consistent with in vivo studies, substantial effort is still required to verify if any of these
processes are related to the development of PD in human patients. Consequently, there is more that
we still do not know about the molecular processes that lead to the development of PD. However, this
study clearly demonstrated the inherent value of combining metabolic studies with traditional cell
biology to explore the molecular mechanisms associated with Parkinson’s disease. Metabolomics is
expected to continue to play an important role in further PD studies.
While avoiding environmental toxins is obvious advice, it is particularly pertinent for individuals
with a genetic predisposition to developing PD. However, we are still far from identifying the
environmental agents that are a current concern to the public and are also linked to an increased
risk in developing PD. For example, most of the research to date has been focused on pesticides
(paraquat and rotenone) with a strong epidemiological association with PD, but whose usage is
restricted and thus are not currently a major risk for human populations. More importantly, it is
clear that a single environmental exposure will not (at least by itself) cause PD, which complicates
the further identification of gene–environment interactions, which, together with aging, may trigger
progressive neurodegeneration.
Since our research strongly suggests that glucose metabolism contributes to PQ toxicity and to
the synergistic effect between PQ and α-synuclein overexpression, a low-carbohydrate diet may be
beneficial to preventing the development and progression of PD [100]. In fact, a ketogenic diet (low
carbohydrate/high fat) has been reported to exert protective effects in PD [101]. To date, there are
no successful therapies to treat or prevent PD. As a result, α-synuclein has garnered a tremendous
amount of attention as a therapeutic target with a number of potential treatments in development or in
clinical trials [102]. These potential drugs are designed to increase α-synuclein clearance, prevent its
aggregation, or inhibit post-translational modifications, but no clinical successes have been observed
as of yet. Correspondingly, an alternative strategy may be to directly target the metabolic processes
“hijacked” by toxins associated with PD. FDA-approved metabolic inhibitors have been safely used
as drugs in humans for decades [103]. While broad-based antioxidant therapies have not had much
success in treating PD [104], a focused effort on developing drugs that inhibit a specific target of
a toxin, such as G6PD in the case of PQ, may be a viable alternative. Furthermore, a personalized
therapy based on a patient’s history of toxin exposure coupled with a ketogenic diet may prove to be a
successful approach to prevent the progression of the disease.
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LDH
LRRK2
LSC
mBCl
MB-PCA

one-dimensional
two-dimensional
three-dimensional
2-deoxy-D-glucose
2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose
6-aminonicotinamide
6-hydroxydopamine
α-synuclein
ascorbic acid
aconitase
Alzheimer’s disease
aspartate 4-decarboxylase
empty adenovirus
adenovirus encoding for human G6PD
adenosine diphosphate
fructose-bisphosphate aldolase
Alanine transaminase
adenosine monophosphate
AMP-activated protein kinase
AMP-activated protein kinase α1
analysis of variance
adenosine triphosphate
blood brain barrier
ATP-citrate synthase
ANOVA of the cross-validated residuals
dihydroxyacetone phosphate
direct infusion-electrospray ionization mass spectrometry
deoxyribonucleic acid
extracellular acidification rate
extraction voltage
fructose-1,6-bisphosphatase I
fumarate hydratase
glucose-6-phosphate dehydrogenase
Glyceraldehyde 3-phosphate dehydrogenase
Glutamate dehydrogenase
Glutaminase
Na+-independent glucose transporters
Aspartate aminotransferase, cytoplasmic
Glucose-6-phosphate isomerase
reduced glutathione
oxidized glutathione
hexokinase
heteronuclear single quantum coherence
isocitrate dehydrogenase
inducible nitric oxide
L-lactate dehydrogenase
leucine-rich repeat kinase 2
succinyl-CoA synthetase
monochlorobimane
multiblock principal component analysis
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MB-PLS
MDH
Mn
MOI
MPP+
MPTP
MS
NAC
NADP
NADPH
NG
NMR
OCR
OGDH
OPLS
OXPHOS
pACC
pAMPK
PBS
PC
PCA
PD
PDH
PET
PFK
PGD
PGK1
PGM
PI
PINK1
PLS
PPP
PQ
PSC
RNA
ROS
RPI
SCV
SDH
SE
SGLT
SNARE
STF-31
SUS
TAL
TCA
TKT
TPI
US
UDP
UMP
WB
WT

multiblock partial least squares
malate dehydrogenase
manganese
multiplicity of infection
1-methyl-4-phenylpyridinium
1-methyl-4-phenyl-1,2, 3, 6-tetrahydropyridine
mass spectrometry
non-amyloid-β component of AD amyloid plaques
nicotinamide adenine dinucleotide phosphate
nicotinamide adenine dinucleotide phosphate hydrogen
glucose free environment
nuclear magnetic resonance spectroscopy
oxygen consumption rate
2-oxoglutarate dehydrogenase
orthogonal projection to latent structures
oxidative phosphorylation
phosphorylated acetyl-CoA carboxylase
phosphorylated AMP-activated protein kinase
phosphate buffered saline
pyruvate carboxylase
principal component analysis
Parkinson’s disease
pyruvate dehydrogenase
positron emission tomography
6-phosphofructokinase 1
6-phosphogluconate dehydrogenase
phosphoglycerate kinase 1
phosphoglucomutase
propidium iodide
phosphatase and tensin homolog (PTEN)-induced kinase 1
partial least squares
pentose phosphate pathway
paraquat
phase-scatter correction
ribonucleic acid
reactive oxygen species
ribose 5-phosphate isomerase A
sampling cone voltage
succinate dehydrogenase
standard error
Na+ -dependent glucose transporters
soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor
4-[[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinyl-benzamide
shared and unique structures
transaldolase
tricarboxylic acid
transketolase
triosephosphate isomerase
United States
uridine diphosphate
uridine monophosphate
Western blot
wild-type
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